


Microemulsion Formulations for the transdermal delivery of testosterone



Rania M. Hathout^{1,2}, Samar Mansour¹, Nahed D. Mortada¹, Ahmed S. Geneidi¹, Richard H. Guy² ¹Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. ²Department of Pharmacy & Pharmacology, University of Bath, Bath, UK.

Introduction

Methodology

zetasizer

c) pH

I- Construction of Phase diagram

b) Conductivity measurements

d) Rheological measurements

drug loading

microemulsions

V- Data Analysis

II- Characterization of microemulsions by

a) Particle size determination using a Malvern

e) FTIR, and ¹H-NMR and ¹³C-NMR spectroscopy

III- Alteration of microemulsion microstructure after

IV- *In vitro* permeation of testosterone from selected

Results fitted to Fick's second law of diffusion to

 $Q = \{KH\}C_{veh} \left[\left(\frac{D}{H^2} t - \frac{1}{6} - \frac{2}{\pi^2} \sum_{n=1}^{\infty} \frac{(-1)^2}{n} \exp(\frac{-Dn^2 \pi^2 t}{H}) \right]$

Permeability coefficient was deduced from the relation:

derive values of KH and D/H²

 $K_p = (KH) \times (D/H^2) = \frac{K.D}{H}$

And the steady-state flux J_{ss} from:

 $J_{SS} = K_p \times C_{veh}$

Testosterone is the major circulating androgen in man.¹ Its deficiency is usually associated with adverse effects on body composition, bone density, sexual function, and mood and may also increase cardiovascular risk. The low molecular weight (M.W.=288) and hydrophobic nature (log $P_{o/w}$ = 3.3 and water solubility = 0.039 mg/ml at 37°C) in addition to first pass metabolism are favourable factors for transdermal delivery of testosterone. It is generally agreed that androgen replacement therapy should deliver physiological amounts (3-10 mg/day) of testosterone. This corresponds to targeted fluxes of 4-14 µg cm⁻² hr⁻¹ over a reasonable surface area of 30 cm². In this work, microemulsions of different compositions were considered to achieve these objectives. Single phase microemulsions are currently of interest to the pharmaceutical scientist as potential drug delivery vehicles due to their long term stability, ease of preparation, and considerable capacity for solubilization of a variety of drug molecules.

Results and Discussion




Fig.1 Effect of chain length on total monophasic area, maximum water of solubilization and minimum amount of surfactant needed for solubilization






Fig.2 The optimum ratio between surfactant (Tween20) and cosurfactant (Transcutol)

Fig.3 Oleic acid / Tween20 / Transcutol / Water phase diagram where the mixing ratio of Tween20: Transcutol is 1:1. 1Φ is the area of one phase region, MΦ is the area of multiple phase regios. Wm is the maximum amount of solubilized water, Sm is the amount of surfactant needed to obtain maximum water solubilization and L20 is a dilution line where the initial oil concentration is 20% (w/w).








Fig.4. Plot of (a) electrical conductivity (σ), (b) (log σ) / t and (c) d(log σ) / d Φ as a function of percentage water content (Φ) along the dilution line L20 A percolation threshold occurs at Φ =2.8 where w/o microemulsion converts to o/w microemulsion.

| | | \mathbf{A} | \mathbf{B} | C | D | ${f E}$ | F |
|--------------------------------|--------------|--------------|--------------|-------|------|---------|------|
| Table 1 Selected microemulsion | Oleic acid | 19 | 18 | 17 | 16.2 | 16 | 15.4 |
| formulations (%w/w). | Tween20 | 38 | 36 | 34 | 32.9 | 32 | 30.8 |
| (70 W/W). | Transcutol | 38 | 36 | 34 | 32.9 | 32 | 30.8 |
| | Water | 5 | 10 | 15 | 18 | 20 | 23 |
| ME | OH frequency | σ (uS/cm) | | n (Pa | s) | | nH |

| Table 2 | ME | OH frequency (cm ⁻¹) | | σ (μS/cm) | | η (Pa.s) | | pН | |
|--|----|-------------------------------------|--------|-------------|-------------|------------------|------------------|-------------|-------------------|
| Changes in the physical | | Unloaded | Loaded | Unloaded | Loaded | Unloaded | Loaded | Unloaded | Loaded |
| parameters of microemulsions | A | 3449 | 3442 | 2.39 ± 0.16 | 2.35 ± 0.21 | 0.047 ± 0.011 | 0.036 ± 0.027 | 5.24 ± 0.01 | 5.30 ± 0.03 |
| after loading with drug (1% w/v). | В | 3436 | 3433 | 3.11 ± 0.27 | 3.63 ± 0.29 | 0.046 ± 0.012 | 0.049 ± 0.020 | 5.15 ± 0.04 | 5.14 ± 0.02 |
| No statistical significant | С | 3434 | 3436 | 4.18 ± 0.64 | 5.04 ± 0.60 | 0.050 ± 0.016 | 0.062 ± 0.008 | 5.04 ± 0.03 | 4.97 ± 0.01 |
| differences between loaded | D | 3426 | 3433 | 5.82 ± 0.53 | 6.35 ± 0.48 | 0.039 ± 0.018 | 0.062 ± 0.007 | 5.03 ± 0.03 | 4.97 ± 0.02 |
| and unloaded microemulsions at P < 0.05. | E | 3431 | 3434 | 7.34 ± 0.23 | 7.20 ± 0.54 | 0.037 ± 0.014 | 0.040 ± 0.017 | 4.89 ± 0.02 | 4.90 ± 0.03 |
| | F | 3401 | 3402 | 8.63 ± 0.59 | 8.71 ± 0.32 | 0.061 ± 0.007 | 0.073 ± 0.037 | 4.45 ± 0.03 | 4.45 ± 0.01 |

According to these results, the drug is present in the oily phase.

Fig.5 Proton NMR and Carbon NMR spectra of microemulsion F.




Table 3. Proton NMR chemical shifts of ME F different functional groups after incorporation of Drug (1% w/v) in ME F.

| Functional | δ (μ | $\Delta oldsymbol{\delta}$ | | |
|--|---------------------------|----------------------------|-------------------------|--|
| group | In ME F (δ ⁰) | In ME F with 1% drug (δ¹) | $(\delta^1 - \delta^0)$ | |
| CH ₃ | 0.855 | 0.888 | 0.031 | |
| CH_2 | 1.162 | 1.191 | 0.029 | |
| CH ₂ CH ₂ C O | 1.543 | 1.571 | 0.028 | |
| CH ₂ CH | 1.989 | 2.02 | 0.031 | |
| CH ₂ CO | 2.208 | 2.23 | 0.022 | |
| OCH ₂ CH ₂ | 3.646 | 3.668 | 0.022 | |
| CH ₂ OCO | 4.171 | 4.190 | 0.019 | |
| ОН | 4.653 | 4.652 | -0.001 | |
| СН | 5.287 | 5.318 | 0.031 | |


Table 4. Carbon NMR chemical shifts of ME F different functional groups after incorporation of Drug (1% w/v) in ME F.


| | | 7 1 | | | | | - 0 | | | | |
|--|-------------------------------|---------------------------------------|---|-------------------------|------------------------|----------------------------|---|-------------------------|------------------------|----------------------------|---|
| | | | | | | | | | | | |
| Oleic acid | | | | Twee | n20 | Transcutol | | | | | |
| δ (ppm) | | | δ (ppm) | | | | δ (ppm) | | | | |
| Functio nal group | ME F (δ ⁰) | ME F with 1% drug | $egin{array}{c} \Delta\delta \ (\delta^1-\ \delta^0) \end{array}$ | Functi onal group | ME F (δ ⁰) | ME F with 1% drug | $egin{array}{c} \Delta\delta \ (\delta^1-\ \delta^0) \end{array}$ | Functi onal group | ME F (δ ⁰) | ME F with 1% drug | $egin{array}{c} \Delta\delta \ (\delta^1-\delta^0) \end{array}$ |
| | | (δ^1) | | | | (δ^1) | | | | (δ^1) | |
| CH ₃ | 14.117 | 14.806 | 0.689 | CH ₃ | 14.088 | 14.161 | 0.07 | CH ₃ | 14.843 | 14.91 6 | 0.0 73 |
| | | | | | | | | С-ОН | 60.863 | 60.91 | 0.0 |
| CH_2 | 22.896 | 22.926 | 0.073 | CH ₂ | 22.896 | 22.926 | 0.07 | | | 4 | 51 |
| - | 29.477 | 29.513 | 0.036 | _ | 29.477 | 29.513 | 3 | C-O | 70.067 | 70.12 | 0.0 |
| | 29.631 30.004 | 29.66 30.034 | 0.029 0.030 | | 29.631 30.004 | 29.66 30.034 | 0.03 | | 72.375 | 6 | 29 |
| | 30.004 | 30.034 | 0.030 | | 30.004 | 30.034 | 0.02 | | | 72.44 | 0.0 |
| | | | | | | | 9 | | | 1 | 66 |
| | | | | | | | 0.03 | | | | |
| | | | | | | | 0 | | | | |
| CH ₂ CH | 25.131 | 25.183 | 0.052 | CH ₂ C | 25.754 | 25.791 | 0.03 | | | | |
| CO | | | | H ₂ CO | | | 7 | | | | |
| $CH_2C=$ | 27.359 | 27.396 | 0.037 | CH ₂ C | 34.086 | 34.130 | 0.04 | | | | |
| С | | | | 0 | | | 4 | | | | |
| CH ₃ CH ₂ CH ₂ | 32.188 | 32.225 | 0.037 | С-ОН | 60.863 | 60.914 | 0.05 | | | | |
| CH ₂ CO | 34.086 | 34.130 | 0.044 | С-О | 70.067 | 70.126 | | | | | |
| | | | | | 70.007 | 70.120 | 9 | | | | |
| C=C | 129.72 | 129.71 | 0.146 | | | , | 0.06 | | | | |
| | 5 | \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ | | | | | 6 | | | | |
| СООН | 175.78 | 175.72 | -0.049 | C=O | 175.78 | 175.73 | _ | | | | |
| | 2 | 3 | | | 2 | 3 | 0.04 | | | | |
| | | | | | | | 9 | | | | |

Oleic acid functional groups are the most affected by testosterone presence. These results confirms the presence of the drug in the internal oily phase with small amounts at the surfactant/cosurfactant interface.

Where is testosterone in the microemulsion droplets?

Fig.6 Schematic diagram showing the position of testosterone and microemulsion components and their interactions.





diffusion.




Fig.8 Permeation of testosterone (3%) from microemulsion E. The results were fitted to Fick's second law of diffusion.

Flux reached targeted values.

Conclusion

The microemulsion system studied offers a potential vehicle for the transdermal delivery of testosterone.

References

[1] Leichtnam ML, Rolland H, Wuthrich P, Guy RH. 2006. Identification of penetration enhancers for testosterone transdermal delivery from spray formulations. J Control Release 113:57-62.

[2] Leichtnam ML, Rolland H, Wuthrich P, Guy RH. 2006. Testosterone hormone replacement therapy: State-of-the-art and emerging technologies. Pharm Res 23:1117-1132.